NCT00316004

Brief Summary

The purpose of this study is to determine if hypertonic saline with and without dextran can improve neurologic outcomes in victims of severe traumatic brain injury (TBI). Injury and lost blood from trauma can cause your body to go into shock (low blood pressure related to blood loss). This decreased blood flow can lead to organ damage. In order to restore the blood pressure and blood flow, the medics give fluids into the patients' veins as soon as possible. This is called "resuscitation". The fluid most commonly used is "isotonic" or one that is the same salt concentration as the blood. The investigators are trying to determine if infusing a "hypertonic" fluid or one more concentrated than the blood can increase the blood pressure and restore blood flow more efficiently. The hypertonic fluids they are using are called hypertonic saline with dextran (HSD) and hypertonic saline (no dextran). Hypertonic saline is a salt solution that is slightly more concentrated than blood. Dextran is a sugar solution.

Trial Health

60
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,331

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started May 2006

Typical duration for phase_3

Geographic Reach
2 countries

12 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 17, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 19, 2006

Completed
12 days until next milestone

Study Start

First participant enrolled

May 1, 2006

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2010

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

May 9, 2011

Completed
Last Updated

May 19, 2011

Status Verified

May 1, 2011

Enrollment Period

3 years

First QC Date

April 17, 2006

Results QC Date

February 11, 2011

Last Update Submit

May 16, 2011

Conditions

Keywords

TraumaticBrain injury

Outcome Measures

Primary Outcomes (2)

  • Glasgow Outcome Scale-Extended (GOSE)≤4 at 6 Months: Completer Analysis

    Glasgow outcome score extended (GOSE) contains eight categories: 1. Dead, 2. Vegetative State (VS), 3. Lower Severe Disability (Lower SD), 4. Upper Severe Disability (Upper SD), 5. Lower Moderate Disability (Lower MD), 6. Upper Moderate Disability (Upper MD), 7. Lower Good Recovery (Lower GR) and 8. Upper Good Recovery (Upper GR). A measured neurological outcome of GOSE≤4 is a poor outcome of severe disability, vegetative state, or death. Completer analysis includes only those patients with GOSE completed at 6 months after injury.

    6 months after injury

  • Glasgow Outcome Scale-Extended (GOSE)≤4 at 6 Months: Imputed Analysis

    Glasgow outcome score extended (GOSE) contains 8 categories: 1. Dead, 2. Vegetative State, 3. Lower Severe Disability, 4. Upper Severe Disability, 5. Lower Moderate Disability, 6. Upper Moderate Disability, 7. Lower Good Recovery and 8. Upper Good Recovery. To adjust for 15% of subjects with absent 6-month GOSE data, an analysis using 20 hot deck imputations for the 6-month GOSE was done using data from patients who were discharged alive based on 1-month post discharge GOSE data or discharge GOSE (if 1-month post discharge data were not available), length of hospital stay, and treatment group.

    6 months after injury

Secondary Outcomes (14)

  • Subgroup of Participants With Head Abbreviated Injury Scores (AIS) Greater Than or Equal to 4 (Head AIS≥4) Assessed to Have Glasgow Outcome Scale-Extended (GOSE)≤4 at 6 Months: Imputed Analysis

    6 months after injury

  • Subgroup of Participants With Head Abbreviated Injury Scores (AIS) Greater Than or Equal to 2 (Head AIS≥2) Assessed to Have Glasgow Outcome Scale-Extended (GOSE)≤4 at 6 Months: Imputed Analysis

    6 months after injury

  • Disability Rating Score (DRS) Categories of Disability

    6 months after injury

  • 28 Day Survival

    28 days after injury

  • Survival at Hospital Discharge up to 6 Months From Date of Injury

    Date of hospital discharge up to 6 months from date of injury

  • +9 more secondary outcomes

Study Arms (3)

7.5% hypertonic saline/6% dextran (HSD)

EXPERIMENTAL

250 ml intravenous bolus administration of 7.5% saline/6% dextran 70

Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD)

7.5% hypertonic saline (HS)

EXPERIMENTAL

250 ml intravenous bolus administration of 7.5% hypertonic saline

Drug: 7.5% Hypertonic Saline (HS)

0.9% normal saline (NS)

PLACEBO COMPARATOR

250 ml intravenous bolus administration of 0.9% saline

Drug: 0.9% Normal Saline (NS)

Interventions

250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.

Also known as: RescueFlo
7.5% hypertonic saline/6% dextran (HSD)

250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.

7.5% hypertonic saline (HS)

250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.

0.9% normal saline (NS)

Eligibility Criteria

Age15 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Blunt trauma
  • Pre-hospital Glasgow Coma Scale equal to or less than 8(GCS≤8)\*
  • Age 15 years or older or 50 kg or more

You may not qualify if:

  • Known or suspected pregnancy
  • Age younger than 15 years or less than 50 kg if age unknown
  • Ongoing pre-hospital cardiopulmonary resuscitation (CPR)
  • Administration of more than 2L crystalloid or any colloid or blood products
  • Severe hypothermia (T less than 28C)
  • Drowning or asphyxia due to hanging
  • Burns TBSA more than 20%
  • Isolated penetrating injury to the head
  • Inability to obtain pre-hospital intravenous access
  • Time of call received at dispatch to study intervention more than four hours
  • Known prisoners

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Alabama Resuscitation Center, University of Alabama

Birmingham, Alabama, 35249, United States

Location

Orange County/UC Irvine

Orange, California, 92868, United States

Location

UCSD-San Diego Resuscitation Research Center

San Diego, California, 92103, United States

Location

Iowa Resuscitation Network, University of Iowa Carver College of Medicine

Iowa City, Iowa, 52242, United States

Location

Portland Resuscitation Outcomes Consortium, Oregon Health & Sciences University

Portland, Oregon, 97239, United States

Location

The Pittsburgh Resuscitation Network, University of Pittsburgh

Pittsburgh, Pennsylvania, 15213, United States

Location

The Regional Medical Center at Memphis

Memphis, Tennessee, 38103, United States

Location

Dallas Center for Resuscitation Research, University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

Location

Seattle-King County Center for Resuscitation Research, University of Washington

Seattle, Washington, 98195, United States

Location

Milwaukee Resuscitation Network, Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

University of Ottawa/University of British Columbia Collaborative RCC, Ottawa Health Research Institute

Ottawa, Ontario, K1Y4E9, Canada

Location

Toronto Regional Resuscitation Research Out-of-Hospital Network, University of Toronto

Toronto, Ontario, M5B1W8, Canada

Location

Related Publications (2)

  • Bulger EM, May S, Brasel KJ, Schreiber M, Kerby JD, Tisherman SA, Newgard C, Slutsky A, Coimbra R, Emerson S, Minei JP, Bardarson B, Kudenchuk P, Baker A, Christenson J, Idris A, Davis D, Fabian TC, Aufderheide TP, Callaway C, Williams C, Banek J, Vaillancourt C, van Heest R, Sopko G, Hata JS, Hoyt DB; ROC Investigators. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA. 2010 Oct 6;304(13):1455-64. doi: 10.1001/jama.2010.1405.

  • Tisherman SA, Schmicker RH, Brasel KJ, Bulger EM, Kerby JD, Minei JP, Powell JL, Reiff DA, Rizoli SB, Schreiber MA. Detailed description of all deaths in both the shock and traumatic brain injury hypertonic saline trials of the Resuscitation Outcomes Consortium. Ann Surg. 2015 Mar;261(3):586-90. doi: 10.1097/SLA.0000000000000837.

MeSH Terms

Conditions

Brain Injuries, TraumaticBrain Injuries

Interventions

Saline Solution, HypertonicDextransSaline Solution

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and Injuries

Intervention Hierarchy (Ancestors)

Hypertonic SolutionsSolutionsPharmaceutical PreparationsGlucansBiopolymersPolymersMacromolecular SubstancesPolysaccharidesCarbohydratesCrystalloid SolutionsIsotonic Solutions

Limitations and Caveats

The trial was stopped early for futility at a planned data and safety monitoring board review. The futility boundary was crossed for each of the 2 group comparisons (hypertonic saline/dextran vs normal saline and hypertonic saline vs normal saline).

Results Point of Contact

Title
Susanne May, PhD
Organization
Clinical Trial Center, University of Washington, Seattle, WA

Study Officials

  • Myron L Weisfeldt, MD

    Resuscitation Outcomes Consortium

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 17, 2006

First Posted

April 19, 2006

Study Start

May 1, 2006

Primary Completion

May 1, 2009

Study Completion

January 1, 2010

Last Updated

May 19, 2011

Results First Posted

May 9, 2011

Record last verified: 2011-05

Locations